High voltage (HV) test environments require dependable visual status indicators to maintain operator safety; however, directly supplying these indicators from HV sources introduces substantial electrical and operational hazards. This work addresses these challenges through the design and implementation of a compact Flyback DC–DC converter that provides galvanic isolation and a stable low-power output specifically intended for LED-based safety beacons. While utilizing Discontinuous Conduction Mode (DCM) and valley-switching to minimize thermal stress, the primary innovation of this design lies in the rigorous optimization of the isolation barrier and PCB architecture to meet HV safety standards (such as IEC 60950-1) within a minimal physical footprint. Transformer parameters were determined using analytical design procedures and subsequently verified by circuit-level simulations, which confirmed correct DCM operation as well as rapid startup behavior without output overshoot. A two-layer PCB was designed in accordance with IPC-2221B standard, with particular emphasis on minimizing parasitic effects and thereby improving overall performance. Experimental characterization demonstrated stable output regulation and a strong correlation between measured and simulated waveforms. The proposed system enhances safety in HV laboratory settings while achieving a compact form factor and supporting a wide input voltage range.
Background: Chronic inflammatory bowel diseases (IBDs), specifically Crohn’s disease and ulcerative colitis, present substantial clinical challenges characterized by a relapsing-remitting course. These conditions often lead to serious complications and significantly impair nutritional status, physical development, and overall quality of life. Methods: This unicentric, prospective, open-label, alternation-based comparative study investigated the efficacy of vitamin D3 supplementation in adolescents with IBD. Patients aged 15–25 years were randomly assigned to receive either 1000 IU/day or 2000 IU/day of cholecalciferol for 6 months as an adjuvant to standard care. Eighty patients completed the study. Results: By month 6, remission was achieved in 52.5% of patients receiving 1000 IU/day (Group A) and 87.5% of those receiving 2000 IU/day (Group B). Significant differences were observed between groups regarding disease activity (p = 0.007), C-reactive protein levels (30.17 ± 15.74 mg/L vs. 62.82 ± 37.14 mg/L; p < 0.001), and fecal calprotectin levels. Conclusions: The machine learning models demonstrated consistent performance in assessing inflammatory indicators, with a weighted average recall exceeding 72% (Random Forest: 82.50%). No adverse effects were reported. Supplementation with 2000 IU/day of vitamin D3 for 6 months was associated with more favorable clinical and biochemical outcomes than 1000 IU/day in this single-center open-label study as an adjunct to standard treatment in adolescents and young adults with IBD. The results suggest that higher doses of vitamin D may be beneficial in achieving remission and reducing systemic inflammation.